Daratumumab With VRd Betters MRD Negativity in Transplant …
WEB2 days ago · Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.
DARZALEX® (daratumumab) subcutaneous (SC) formulation …
WEB9 hours ago · CEPHEUS is an international, randomised, open-label, Phase 3 study comparing subcutaneous daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) with standard bortezomib, lenalidomide, and dexamethasone (VRd). 1 The trial enrolled 395 patients with newly diagnosed multiple myeloma who …
DARZALEX FASPRO®-based quadruplet regimen significantly …
WEB2 days ago · The DARZALEX -based quadruplet regimen, compared to VRd, also significantly increased the depth of response with higher rates of CR or better. The CR or better rate was 81.2 percent with D-VRd vs ...
J&J Posts Positive Phase III Results for Carvykti and ... - BioSpace
WEB2 hours ago · J&J used its IMS presentation to share Phase III data on the use of Darzalex Faspro, the subcutaneous formulation of the drug, with bortezomib, lenalidomide and dexamethasone (VRd) in the treatment of patients with newly diagnosed multiple myeloma. Sanofi recently won FDA approval to use its rival CD38 drug Sarclisa with VRd in …
J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD …
WEB2 days ago · The DARZALEX FASPRO-based quadruplet regimen, compared to VRd, also significantly increased the depth of response with higher rates of CR or better.
CEPHEUS Outcomes Support Daratumumab Plus VRd as SOC in …
WEB2 days ago · CEPHEUS Outcomes Support Daratumumab Plus VRd as SOC in Multiple Myeloma. Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center ...
Myeloma: Daratumumab Plus Lenalidomide Improves MRD …
WEB8 hours ago · Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal residual disease.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
WEBDec 12, 2023 · An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple ...
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for …
WEBJun 3, 2024 · Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma.